← Back to all trials
Recruiting
NCT07501702
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Conditions: Myasthenia Gravis, Generalized
Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 30
Sponsor: Vertex Pharmaceuticals Incorporated
Location: Tri Valley Neurology Medical Associates Inc. Mission Hills California
Summary
The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
Eligibility Criteria
Key Inclusion Criteria:
* Age 18-80 years
* Diagnosis of generalized myasthenia gravis with generalized muscle weakness and fitting MGFA clinical classification II-IV
* Additional inclusion criteria are defined in the protocol
Key Exclusion Criteria:
* History of thymic surgery within 6 months of screening
* History of malignancy within the last 5 years
* Additional exclusion criteria are defined in the protocol
Other protocol defined Inclusion/Exclusion criteria will apply.
Source: ClinicalTrials.gov (NCT07501702). StuddyBuddy aggregates publicly available trial information.
